Search Results

BioMidwest

Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-AF device that uses AI to help identify patients who may be at increased risk of atrial fibrillation/flutter (AF).

June 26, 2024

·

5 min read

Business

Tempus to Report Third Quarter 2024 Financial Results on November 7

October 24, 2024

·

1 min read

Press Releases

Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology

October 21, 2024

·

4 min read

Business

Tempus Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced a new collaboration with United Therapeutics (UT), a leading biotechnology company focused on providing a brighter future for patients through the development of novel pharmaceuticals and technologies.

June 25, 2024

·

5 min read

Press Releases

Tempus Announces Collaboration With JW Pharmaceutical to Apply Real-World Data and Biological Modeling to Enhance Early Research and Development

October 28, 2024

·

5 min read

Business

Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024

September 13, 2024

·

6 min read

Press Releases

Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development

September 27, 2024

·

5 min read

BioMidwest

Tempus Announces 18 Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2024

Tempus, a leader in artificial intelligence and precision medicine, today announced 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 5-10, in San Diego, California.

April 5, 2024

·

3 min read

BioMidwest

Tempus Releases New Data at AACR Showcasing Ways to Analyze Multimodal Data to Highlight Potential Therapeutic Routes for HER2-Directed Antibody-Drug Conjugates in Several Tumor Types

Tempus, a leader in artificial intelligence and precision medicine, will present new data along with Pfizer at the AACR 2024 Annual Meeting.

April 8, 2024

·

2 min read

BioMidwest

Tempus Introduces xM to Assess Minimal Residual Disease (MRD) in Patients with Colorectal Cancer (CRC) for Research Use Only

Tempus, a leader in artificial intelligence and precision medicine, announced the addition of a novel MRD assay, xM, to its comprehensive testing solutions.

January 18, 2024

·

3 min read